1. Market Research
  2. > Apogenix GmbH - Product Pipeline Review - 2013

Apogenix GmbH - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Apogenix GmbH - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Apogenix GmbH - Product Pipeline Review - 2013” provides data on the Apogenix GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Apogenix GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from Apogenix GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Apogenix GmbH - Brief Apogenix GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Apogenix GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Apogenix GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Apogenix GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Apogenix GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Apogenix GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Apogenix GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Apogenix GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Apogenix GmbH and identify potential opportunities in those areas.

Table Of Contents

Apogenix GmbH - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Apogenix GmbH Snapshot 4
Apogenix GmbH Overview 4
Key Information 4
Key Facts 4
Apogenix GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
Apogenix GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Apogenix GmbH - Pipeline Products Glance 9
Apogenix GmbH Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Apogenix GmbH - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Apogenix GmbH - Drug Profiles 12
APG-101 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
APG-350 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
IL-4 Blocker 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Apogenix GmbH - Pipeline Analysis 15
Apogenix GmbH - Pipeline Products by Therapeutic Class 15
Apogenix GmbH - Pipeline Products By Target 16
Apogenix GmbH - Pipeline Products by Route of Administration 17
Apogenix GmbH - Pipeline Products By Mechanism of Action 18
Apogenix GmbH - Recent Pipeline Updates 19
Apogenix GmbH - Dormant Projects 21
Apogenix GmbH - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24



List of Tables

Apogenix GmbH, Key Information 4
Apogenix GmbH, Key Facts 4
Apogenix GmbH - Pipeline by Indication, 2013 6
Apogenix GmbH - Pipeline by Stage of Development, 2013 7
Apogenix GmbH - Monotherapy Products in Pipeline, 2013 8
Apogenix GmbH - Phase II, 2013 9
Apogenix GmbH - Phase I, 2013 10
Apogenix GmbH - Preclinical, 2013 11
Apogenix GmbH - Pipeline By Therapeutic Class, 2013 15
Apogenix GmbH - Pipeline By Target, 2013 16
Apogenix GmbH - Pipeline By Route of Administration, 2013 17
Apogenix GmbH - Pipeline Products By Mechanism of Action, 2013 18
Apogenix GmbH - Recent Pipeline Updates, 2013 19
Apogenix GmbH - Dormant Developmental Projects,2013 21



List of Figures

Apogenix GmbH - Pipeline by Indication, 2013 6
Apogenix GmbH - Pipeline by Stage of Development, 2013 7
Apogenix GmbH - Monotherapy Products in Pipeline, 2013 8
Apogenix GmbH - Pipeline By Route of Administration, 2013 17
Apogenix GmbH - Pipeline Products By Mechanism of Action, 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.